UniQure's gene therapy for a specific ALS type gets safety nod, plans more patient trials.

UniQure, a gene therapy company, received a positive safety review for its AMT-162 treatment for a specific type of ALS from an independent committee. The therapy targets ALS caused by mutations in the SOD1 gene. The company plans to enroll more patients in the first quarter of 2025 to further test the safety and potential effectiveness of the treatment.

2 months ago
3 Articles

Further Reading